REC 3565
Alternative Names: EXS-73565; REC-3565; ‘565Latest Information Update: 29 Nov 2024
Price :
$50 *
At a glance
- Originator Exscientia
- Developer Bristol-Myers Squibb; Recursion Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action MALT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer